Coherus BioSciences, Inc. (CHRS)
US — Healthcare Sector
Automate Your Wheel Strategy on CHRS
With Tiblio's Option Bot, you can configure your own wheel strategy including CHRS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CHRS
- Rev/Share 1.7046
- Book/Share -1.5836
- PB -0.4718
- Debt/Equity -1.2614
- CurrentRatio 1.2162
- ROIC -0.9875
- MktCap 86625138.0
- FreeCF/Share 0.0043
- PFCF 173.2503
- PE -0.6611
- Debt/Assets 0.6237
- DivYield 0
- ROE 1.0743
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | CHRS | UBS | Buy | Neutral | $4 | $1.5 | Aug. 16, 2024 |
News
About Coherus BioSciences, Inc. (CHRS)
- IPO Date 2014-11-06
- Website https://www.coherus.com
- Industry Biotechnology
- CEO Mr. Dennis M. Lanfear
- Employees 228
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.